A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826

Castellino SM;Li H;Herrera AF;LeBlanc ML;Parsons SK;Unger JM;Punnett A;Hodgson D;Keller FG;Drachtman RA;Lamble A;Forlenza CJ;Doan A;Rutherford SC;Evens AM;Little RF;Smith MA;Hoppe BS;Song JY;Smith SM;Friedberg JW;Kelly KM Journal of Clinical Oncology. 2026 Jan 9; JCO2500203. DOI: 10.1200/JCO-25-00203.

PMid: PMID41512237 | PMC number: 13192332

Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826)

Ahmed S Blood Adv. 2026 Jul 29:bloodadvances.2026021402. doi: 10.1182/bloodadvances.2026021402.

PMid: 42526889

Nivolumab + Doxorubicin, Vinblastine, and Dacarbazine in HIV-Associated Advanced-Stage Classic Hodgkin Lymphoma

Goyal G;Lurain K;Lopez G;Rutherford SC;Castellino SM;Davison K;Evens A;Smith SM;Kelly K;LeBlanc M;Song JY;Odeny T;Ratner Lee;Friedberg JW;Herrera AF JCO Oncol Adv . 2026 Jan;3(1):e2500143. doi: 10.1200/oa-25-00143. Epub 2026 Feb 26.

PMid: 42577949 | PMC number: PMC13456540

Nivolumab-AVD versus brentuximab vedotin-AVD in older patients with advanced stage classic Hodgkin lymphoma

S Rutherford;H Li;A Herrera;M LeBlanc;S Ahmed;K Davison;S Parsons;J Unger;A Perry;C Casulo;N Bartlett;J Tuscano;B Hess;P Torka;P Kumar;R Jacobs;J Song;S Castellino;B Kahl;J Leonard;S Smith;J Friedberg;A Evens Journal of Clinical Oncology; JCO2500204; epub 16 Jun 2025. Sep 20;43(27):2968-2973. doi: 10.1200/JCO-25-00204.

PMid: PMID40523203 | PMC number: 12353409

Prognostic Value of Circulating Tumor DNA in Advanced Stage Classic Hodgkin Lymphoma Patients Treated on SWOG S1826

J Paczkowska;M Kaczkowiak;M LeBlanc;C Stewart;A Herrera;J Fernando del Castillo;S Castellino;S Rutherford;A Evens;K Davison;H Li;D Neuberg;M Murakami;J Makker;B Kahl;J Leonard;N Bartlett;S Smith;J Song;K Kelly;G Getz;JW Friedberg;M Shipp ICML 2025 Meeting (Lugano, Switzerland, from 17 to 21 June 2025)

The Influence of Age on Patient-Reported Outcomes (PROs) Endpoints on the S1826 Cross-Network Phase III trial of Advanced-Stage, Classic Hodgkin Lymphoma (cHL) (3891/4500)

K Davison;J Unger;H Li;S Castellino;H Dillon;T Hernandez;S Rutherford;A Punnett;M LeBlanc;J Song;S Smith;A Evens;K Kelly;J Friedberg;A Herrera;S Parsons ASH Annual Meeting (December 6-9, 2025, Orlando, FL). poster abstract 2738. Blood (2025) 146 (Supplement 1): 2738

3-Year Follow-up of the S1826 Study Confirms Improved Progression-Free Survival with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma

A Herrera;M LeBlanc;S Castellino;H Li;S Rutherford;A Evens;K Davison;A Punnett;S Parsons;S Ahmed;C Casulo;N Bartlett;J Tuscano;M Mei;B Hess;R Jacobs;B Hu;C Moskowitz;C Forlenza;A Doan;A Lamble;D Hodgson;M Knopp;P Hernandez;R Little;M Shipp;RM Crump;B Kahl;JP Leonard;S Smith;J Song;K Kelly;J Friedberg ASH Annual Meeting (December 6-9, 2025, Orlando, FL). #151 oral. Blood (2025) 146 (Supplement 1): 151.

CtDNA Analyses of Molecular Tumor Burden Improve Response Assessment in Patients with Advanced Stage Classic Hodgkin Lymphoma Treated on SWOG S1826

J Paczkowska;M Kaszkowiak;M LeBlanc;C Stewart;A Herrera;J Fernandez del Castillo;S Castellino;S Rutherford;A Evens;K Davison;H Li;D Neuberg;M Murakami;J Makker;B Kahl;J Leonard;N Bartlett;S Smith;J Song;K Kelly;G Getz;JW Friedberg;M Shipp ASH Annual Meeting (December 6-9, 2025, Orlando, FL). oral #351. Blood (2025) 146 (Supplement 1): 351. 10.1182/blood-2025-351

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?

P Torka;A Bock;E Nazarenko;Y Xu;J Vaughn;S Thiruvengadam;A Major;K Sekaran;D Reef;C Lee;G Smilnak;E Luttwak;V Patel;H Shah;A Ip;G Baek;R Mynam;D Sano;D Gerber;A Falade;M Palmeri;R Mrad;M Iqbal;J Sharp;T Voorbees;P Geethakumari;J Rbodes;U Durani;H Cherng;Y Karimi;P Pophali;M Di;T Feldman;J Svoboda;K Shanmugasundaram;A Niu;N Grover;R Karmali;A Herrera;C Diefenbach;N Epperla ASH Annual Meeting (December 6-9, 2025, Orlando, FL). #3622 poster. Blood (2025) 146 (Supplement 1): 3622

Clinical prognostication in the SWOG 1826 randomized clinical trial of nivolumab-AVD versus brentuximab-AVD: Performance of the advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI)

C Casulo;H Li;A Herrera;S Castellino;S Rutherford;K Davison;A Punnett;B Kahl;J Leonard;S Smith;J Song;K Kelly;J Friedberg;M LeBlanc;S Parsons;A Rodday;A Evens ASH Annual Meeting (December 6-9, 2025, Orlando, FL), #154 oral. Blood (2025) 146 (Supplement 1): 154

Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study

Nancy Bartlett, MD;Hongli Li;Michael Knopp;Chad Wright;Heiko Schoder;Lawrence Schwartz;Sharon Castellino;Sarah Rutherford;Andrew Evens;Kelly Davison;Angela Punnett;Margaret Shipp;Brad Kahl;John Leonard;Sonali Smith;Joo Song;Lale Kostakoglu;Kara Kelly;Michael LeBlanc;Jonathan Friedberg;Alex Herrera ASH Annual Meeting (December 6-9, 2025, Orlando, FL), 2025. Abstract 1851 poster. Blood (2025) 146 (Supplement 1): 1851

IMPACT OF EBV STATUS AND HISTOLOGY ON OUTCOMES WITH NIVOLUMAB-AVD VERSUS Bv-AVD IN PATIENTS ENROLLED ON SWOG S1826

S. Ahmed;H. Li;A. F Herrera;A. Perry;A. E Kovach;K. Davison;S. C Rutherford;S. Castellino;A. Evens;B. Kahl;N. Bartlett;J. P Leonard;M. A Shipp;S. M Smith;K. Kelly;M. LeBlanc;J. W Friedberg;J. Y Song ICML 2025 Meeting (Lugano, Switzerland, from 17 to 21 June 2025), e20_70093

HEALTH-RELATED QUALITY OF LIFE (HRQoL) ENDPOINTS OF THE PHASE III INTERGROUP S1826 ADVANCED-STAGE, CLASSIC HODGKIN LYMPHOMA (cHL) TRIAL

J. M. Unger;H. Li;A. F. Herrera;K. Davison;S. M. Castellino;H. Dillon;T. Hernandez;S. C. Rutherford;A. Punnett;M. LeBlanc;J. Y. Song;S. M. Smith;A. M. Evens;K. M. Kelly;J. W. Friedberg;S. K. Parsons ICML 2025 Meeting (Lugano, Switzerland, from 17 to 21 June 2025), e127_70093

THE ASSOCIATION OF SOCIAL DISADVANTAGE WITH OUTCOMES IN PATIENTS WITH ADVANCED-STAGE, CLASSIC HODGKIN LYMPHOMA ENROLLED IN THE PHASE 3 INTERGROUP TRIAL S1826

J. M. Kahn;J. M. Unger;H. Li;S. M. Castellino;H. Dillon;T. Hernandez;S. C. Rutherford;A. Punnett;M. LeBlanc;J. Y. Song;S. M. Smith;A. M. Evens;K. M. Kelly;J. W. Friedberg;A. Herrera ICML 2025 Meeting (Lugano, Switzerland, from 17 to 21 June 2025), e368_70093

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma. Reply

Herrera AF;LeBlanc M;Friedberg JW N Engl J Med. 2025 Jan 2;392(1):102. doi: 10.1056/NEJMc2414269

PMid: PMID39752312

Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826

Rutherford SC;Li H;Herrera AF;LeBlanc ML;Ahmed S;Davison K;Parsons SK;Unger JM;Perry AM;Casulo C;Bartlett NL;Tuscano JM;Hess BT;Torka P;Kumar P;Jacobs R;Song JY;Castellino SM;Kahl B;Leonard JP;Smith SM;Friedberg JW;Evens AM Journal of Clinical Oncology. 2025 Sep 20; 43: 2968-2973. DOI: 10.1200/JCO-25-00204.

Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children

A Lo;A Liu;Q Liu;Y Yasui;S Catellino;K Kelly;A Hererra;JW Friedberg;D Friedman;C Schwartz;Q Pei;S Kessel;S Bergeron-Gravel;H Dama;K Roberts;L Constine;D Hodgson JAMA Network Open Jan 2;7(1):e2351062

PMid: PMID38241048 | PMC number: PMC10799264

Nivolumab-AVD or Standard of Care in Advanced Stage Classic Hodgkin Lymphoma

A Herrera;M LeBlanc;S Castellino;H Li;S Rutherford;A Evens;K Davison;A Punnett;S Parsons;S Ahmed;C Casulo;N Bartlett;J Tuscano;M Mei;B Hess;R Jacobs;H Saeed;P Torka;B Hu;C Moskowitz;S Kaur;G Goyal;C Forlenza;A Doan;A Lamble;P Kumar;S Chowdury;B Brinker;N Sharma;A Singh;K Blum;A Perry;A Kovach;D Hodgson;L Constine;L Kostakoglu Shields;A Prica;H Dillon;R Little;M Shipp;M Crump;B Kahl;J Leonard;S Smith;J Song;K Kelly;JW Friedberg New England Journal of Medicine Oct 17;391(15):1379-1389

PMid: PMID39413375 | PMC number: PMC11488644

Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL)

S Castellino;H Li;A Herrera;A Punnett;M LeBlanc;S Parsons;F Keller;R Drachtman;A Lambert;C Forlenza;A Doan;S Rutherford;A Evens;D Hodgson;R Little;M Smith;H Dillon;J Song;S Smith;J Friedberg;K Kelly ISHL (October 26-28, Cologne, Germany), oral

Nivolumab-AVD improves 2-year progression-free and overall survival compared to Bv-AVD in older patients (aged =60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826

S Rutherford;H Li;A Herrera;M LeBlanc;S Ahmed;K Davison;C Casulo;N Bartlett;J Tuscano;B Hess;P Torka;P Kumar;R Jacobs;J Song;B Kahl;J Leonard;S Smith;JW Friedberg;A Evens ISHL (October 26-28, Cologne, Germany), oral

Pediatric and Adolescent Hodgkin Lymphoma: Paving the Way for Standards of Care and Shared Decision Making

J Kahn;C Mauz-Korholz;T Hernandez;S Milgrom;S Castellino ASCO Educational Book

2-Year Follow-up of the S1826 Study Confirms Improved Progression-Free Survival with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma

A Herrera;M LeBlanc;S Castellino;H Li;S Rutherford;A Evens;K Davison;A Punnett;S Parsons;S Ahmed;C Casulo;N Bartlett;J Tuscano;M Mei;B Hess;R Jacobs;H Saeed;P Torka;B Hu;C Moskowitz;S Kaur;G Goyal;C Forlenza;A Doan;A Lamble;P Kumar;S Chowdury;B Brinker;N Sharma;A Singh;K Blum;A Perry;A Kovach;D Hodgson;L Constine;L Kostakoglu Shields;A Prica;H Dillon;R Little;M Shipp;M Crump;B Kahl;J Leonard;S Smith;J Song;K Kelly;JW Friedberg ISHL (October 26-28, 2024 Cologne, Germany), oral

Nivolumab-AVD Improves Progression-Free Survival (PFS) Compared to Brentuximab Vedotin-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL), Results of SWOG S1826

A Herrera;H Li;S Costellino;S Rutherford;A Evens;K Davidson;A Punnett;D Hodgson;S Parsons;S Ahmed;C Casulo;N Bartlett;J Song;R Little;M LeBlanc;B Kahl;J Leonard;K Kelly;S Smith;J Friedberg J Clin Oncol 41, 2023 (suppl 17; abstr LBA4); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral plenary session

Nivolumab-AVD Improves Progression-Free Survival (PFS) Compared to Brentuximab Vedotin-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL), Results of SWOG S1826

A Herrera;M LeBlanc;S Castellino;H Li;S Rutherford;A Evens;K Davison;A Punnett;D Hodgson;S Parsons;S Ahmed;C Casulo;N Bartlett;J Tuscano;M Mei;B Hess;R Jacobs;H Saeed;P Torka;B Hu;C Moskowitz;S Kaur;G Goyal;C Forlenza;A Doan;A Lamble;P Kumar;S Chowdury;B Brinker;N Sharma;A Singh;K Blum;W Macon;A Perry;A Kovach;L Constine;L Kostakoglu Shields;A Prica;R Little;M Shipp;M Crump;B Kahl;J Leonard;S Smith;J Song;K Kelly;JW Friedberg Hematology Oncology Vol 41 Issue S2 Supplement; ICML (June 13 to June 17, 2023, Lugano, Switzerland), oral, plenary session

Progression-Free Survival (PFS) and toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

S Castellino;H Li;A Herrera;A Punnett;M LeBlanc;F Keller;R Drachtman;A Lamble;C Forlenza;A Doan;S Rutherford;A Evens;D Hodgson;S Parsons;R Little;M Smith;J Song;S Smith;JW Friedberg;K Kelly ASH Annual Meeting (Dec 9-12, 2023, San Diego), oral

Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged =60 years) enrolled on SWOG S1826

S Rutherford;H Li;A Herrera;M LeBlanc;S Ahmed;K Davison;C Casulo;N Bartlett;J Tuscano;B Hess;P Torka;P Kumar;R Jacobs;J Song;S Castellino;B Kahl;J Leonard;S Smith;JW Friedberg;A Evens ASH Annual Meeting (Dec9-12,2023, San Diego, CA), oral

An Intergroup Approach for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Adolescents and Young Adults (AYA): SWOG S1826

S Castellino;M Leblanc;A Herrera;S Parsons;A Punnett;D Hodgson;S Rutherford;N Kahn;L Constine;K Davidson;A Prica;JW Friedberg;K Kelly INTERNATIONAL SYMPOSIUM ON CHILDHOOD, ADOLESCENT AND YOUNG ADULT HODGKIN LYMPHOMA (ISCAYAHL) (5/13-16/20, Berlin, Germany)

The Evolution of Children’s Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity

A Lo;A Liu;Y Yasui;S Castellino;K Kelly;A Herrera;JW Friedberg;D Friedman;C Schwartz;K Roberts;L Constine;D Hodgson American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #881

Addressing the Paucity of AYA Clinical Trials Through Pediatric and Adult Partnership

S Parsons;M Roth AYA Global Congress (December 2, 2021), plenary presentation, oral, no publication

An Intergroup Collaboration for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Adolescents and Young Adults (AYA): SWOG S1826

S Castellino;M LeBlanc;A Herrera;S Parsons;S Punnett;D Hodgson;S Rutherford;N Kahn;L Constine;K Davidson;A Prica;JW Friedberg;K Kelly J Clin Oncol 38: 2020 (suppl; abstr TPS8067); American Society of Clinical Oncology 2020 Annual Meeting, TIPS poster

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma (SWOG Intergroup S1826)

A Herrera;B Kahl Hematologist [Clinical Trials Corner] Sept 1 Vol 17, Issue 5

Reply to LTE, Interim PET assessment of advanced Hodgkin Lymphoma: is it sufficient? [Letter to Editor]

D Stephens;H Schoder;H Li;J Friedberg Journal of Nuclear Medicine Sep 11;jnumed.120.242685. doi: 10.2967/jnumed.120.242685. Online ahead of print.

PMid: PMID32917781

SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

A Herrera;H Li;S Castellino;S Rutherford;A Evens;K Davidson;A Punnett;L Constine;D Hodgson;S Parsons;A Prica;L Kostakoglu;M Shipp;M Leblanc;C Laubach;M Crump;B Kahl;JP Leonard;K Kelly;S Smith;JW Friedberg American Society of Hematology (December 5-8, 2020, virtual), poster presentation

Evaluation of Activation of a National Cancer Trials Network (NCTN) trial for Hodgkin Lymphoma (HL) at Children’s Oncology Group (COG) Institutions

S Castellino;A Punnett;S Parsons;N Degroote;S Muehle;M Roth;A Herrera;JW Friedberg;N Siebel;K Kelly American Society of Hematology (December 5-8, 2020, virtual), poster presentation